← Back to headlines
FDA Extends Review of Biogen's Alzheimer's Drug Leqembi
The U.S. Food and Drug Administration (FDA) has extended its review period for Biogen's Alzheimer's injection, Leqembi, delaying a decision on its approval.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
